Dydrogesterone indications beyond menopausal hormone therapy: an evidence review and woman’s journey

References

• Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009;65 (Suppl 1):S3–S11.
   PubMed Web of Science ®Google Scholar
• Schindler AE. Dydrogesterone-a unique progestogen. Maturitas. 2009;65 (Suppl 1):S1.
   PubMed Web of Science ®Google Scholar
• Bińkowska M, Woroń J. Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015;14:134–143.
   PubMedGoogle Scholar
• Mueck AO, Seeger H, Bühling KJ. Use of dydrogesterone in hormone replacement therapy. Maturitas. 2009;65 (Suppl 1):S51–S60.
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Panay N, Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety. Maturitas. 2013;76:10–21.
   PubMed Web of Science ®Google Scholar
• Bernardi M, Lazzeri L, Perelli F, et al. Dysmenorrhea and related disorders. F1000Res. 2017;6:1645.
   PubMedGoogle Scholar
• French L. Dysmenorrhea. Am Fam Physician. 2005;71:285–291.
   PubMed Web of Science ®Google Scholar
• Nagy H, Khan MAB. Dysmenorrhea. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
   Google Scholar
• Latthe PM, Champaneria R, Khan KS. Dysmenorrhoea. BMJ Clin Evid. 2011;2011:0813.
   PubMedGoogle Scholar
• Pattanittum P, Kunyanone N, Brown J, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016;3:CD002124.
   PubMedGoogle Scholar
• Saei Ghare Naz M, Kiani Z, Rashidi Fakari F, et al. The effect of micronutrients on pain management of primary dysmenorrhea: a systematic review and meta-analysis. J Caring Sci. 2020;9:47–56.
   PubMedGoogle Scholar
• Marjoribanks J, Ayeleke RO, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;2015:CD001751.
   PubMedGoogle Scholar
• Taniguchi F, Ota I, Iba Y, et al. The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: an open-label multicenter clinical study. J Obstet Gynaecol Res. 2019;45:168–175.
   PubMed Web of Science ®Google Scholar
• Stone S, Khamashta MA, Nelson-Piercy C. Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link? Drug Saf. 2002;25:545–551.
   PubMed Web of Science ®Google Scholar
• Schweppe KW. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009;65 (Suppl 1):S23–S27.
   PubMed Web of Science ®Google Scholar
• Ely JW, Kennedy CM, Clark EC, et al. Abnormal uterine bleeding: a management algorithm. J Am Board Fam Med. 2006;19:590–602.
   PubMed Web of Science ®Google Scholar
• Farrukh JB, Towriss K, McKee N. Abnormal uterine bleeding: taking the stress out of controlling the flow. Can Fam Physician. 2015;61:693–697.
   PubMed Web of Science ®Google Scholar
• Podzolkova N, Tatarchuk T, Doshchanova A, et al. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol. 2016;32:246–249.
   PubMed Web of Science ®Google Scholar
• Trivedi N, Chauhan N, Vaidya V. Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study. Gynecol Endocrinol. 2016;32:667–671.
   PubMed Web of Science ®Google Scholar
• Stute P, Bodmer C, Ehlert U, et al. Interdisciplinary consensus on management of premenstrual disorders in Switzerland. Gynecol Endocrinol. 2017;33:342–348.
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;218:68–74.
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Brown J, O'Brien PM, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013;2013:CD001396.
   Google Scholar
• Green LJ, O’Brien PMS, Panay N, et al. Management of premenstrual syndrome: green-top guideline no. 48. BJOG. 2017;124:e73–e105.
   PubMed Web of Science ®Google Scholar
• Lete I, Lapuente O. Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review. Open Access J Contracept. 2016;7:117–125.
   PubMed Web of Science ®Google Scholar
• Ford O, Lethaby A, Roberts H, et al. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2012:CD003415.
   Google Scholar
• Dennerstein L, Morse C, Gotts G, et al. Treatment of premenstrual syndrome. A double-blind trial of dydrogesterone. J Affect Disord. 1986;11:199–205.
   PubMed Web of Science ®Google Scholar
• Sampson GA, Heathcote PR, Wordsworth J, et al. Premenstrual syndrome. A double-blind cross-over study of treatment with dydrogesterone and placebo. Br J Psychiatry. 1988;153:232–235.
   PubMed Web of Science ®Google Scholar
• Hoffman V, Pedersen PA, Philip J, et al. The effect of dydrogesterone on premenstrual symptoms. a double-blind, randomized, placebo-controlled study in general practice. Scand J Prim Health Care. 1988;6:179–183.
   PubMedGoogle Scholar
• Khajehei M, Abdali K, Parsanezhad ME, et al. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet. 2009;105:158–161.
   PubMed Web of Science ®Google Scholar
• Gün İ, Özdamar Ö, Yılmaz A. Luteal phase support in intrauterine insemination cycles. Turk J Obstet Gynecol. 2016;13:90–94.
   PubMed Web of Science ®Google Scholar
• Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016;32:97–106.
   PubMed Web of Science ®Google Scholar
• Balasch J, Vanrell JA, Márquez M, et al. Dehydrogesterone versus vaginal progesterone in the treatment of the endometrial luteal phase deficiency. Fertil Steril. 1982;37:751–754.
   PubMed Web of Science ®Google Scholar
• Khosravi D, Taheripanah R, Taheripanah A, et al. Comparison of oral dydrogesterone with vaginal progesterone for luteal support in IUI cycles: a randomized clinical trial. Iran J Reprod Med. 2015;13:433–438.
   PubMedGoogle Scholar
• Taş M, Uludag SZ, Aygen ME, et al. Comparison of oral dydrogesterone and vaginal micronized progesterone for luteal phase support in intrauterine insemination. Gynecol Endocrinol. 2020;36:77–80.
   PubMed Web of Science ®Google Scholar
• Malhotra J, Krishnaprasad K. Open-label, prospective, investigator initiated study to assess the clinical role of oral natural or synthetic progesterone during stimulated IUI cycles for unexplained infertility. J Clin Diagn Res. 2016;10:QC08–QC10.
   PubMed Web of Science ®Google Scholar
• van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;2015:CD009154.
   PubMedGoogle Scholar
• Tomic V, Kasum M, Vucic K. The role of luteal support during IVF: a qualitative systematic review. Gynecol Endocrinol. 2019;35:829–834.
   PubMed Web of Science ®Google Scholar
• Barbosa MWP, Valadares NPB, Barbosa ACP, et al. Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis. JBRA Assist Reprod. 2018;22:148–156.
   PubMed Web of Science ®Google Scholar
• Griesinger G, Blockeel C, Sukhikh GT, et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018;33:2212–2221.
   PubMed Web of Science ®Google Scholar
• Alves C, Rapp A. Spontaneous abortion (miscarriage). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
   Google Scholar
• Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol. 2012;28:983–990.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Park TC, Kim JH, et al. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. Biomed Res Int. 2017;2017:3616875.
   PubMed Web of Science ®Google Scholar
• Gerhard I, Gwinner B, Eggert-Kruse W, et al. Double-blind controlled trial of progesterone substitution in threatened abortion. Biol Res Pregnancy Perinatol. 1987;8:26–34.
   PubMedGoogle Scholar
• Palagiano A, Bulletti C, Pace MC, et al. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann N Y Acad Sci. 2004;1034:200–210.
   PubMed Web of Science ®Google Scholar
• Czajkowski K, Sienko J, Mogilinski M, et al. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril. 2007;87:613–618.
   PubMed Web of Science ®Google Scholar
• El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas. 2009;65 (Suppl):S43–S46.
   Web of Science ®Google Scholar
• Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009;65Suppl:S47–S50.
   Google Scholar
• Alimohamadi S, Javadian P, Gharedaghi MH, et al. Progesterone and threatened abortion: a randomized clinical trial on endocervical cytokine concentrations. J Reprod Immunol. 2013;98:52–60.
   PubMed Web of Science ®Google Scholar
• Yassaee F, Shekarriz-Foumani R, Afsari S, et al. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. J Reprod Infertil. 2014;15:147–151.
   PubMedGoogle Scholar
• Omar MH, Mashita MK, Lim PS, et al. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol. 2005;97:421–425.
   PubMed Web of Science ®Google Scholar
• Siew JYS, Allen JC, Hui CYY, et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 2018;228:319–324.
   PubMed Web of Science ®Google Scholar
• Eshre Guideline Group On RPL, Bender Atik R, Christiansen OB, et al. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open. 2018;2018:hoy004.
   PubMedGoogle Scholar
• Qureshi NS. Treatment options for threatened miscarriage. Maturitas. 2009;65 (Suppl 1):S35–S41.
   PubMed Web of Science ®Google Scholar
• Saccone G, Schoen C, Franasiak JM, et al. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2017;107:430–438.e3.
   PubMed Web of Science ®Google Scholar
• Carp H. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol. 2015;31:422–430.
   PubMed Web of Science ®Google Scholar